<DOC>
	<DOCNO>NCT01511367</DOCNO>
	<brief_summary>This comparator study assess safety efficacy Flutiform compare Fluticasone pMDI Seretide pMDI paediatric asthma patient moderate severe persistent , reversible asthma .</brief_summary>
	<brief_title>Comparison Flutiform , Fluticasone Seretide Treatment Moderate Severe Asthma Paediatric Patients</brief_title>
	<detailed_description>This study involve 2-4 week run-in phase follow 12 week double blind treatment phase . During run-in phase , subject receive Flixotide . In treatment phase subject randomise one 3 treatment group receive active Flutiform placebo Flixotide Active Seretide placebo Flixotide active Flixotide either placebo seretide placebo Flutiform . Efficacy assess lung function test , asthma symptom , sleep disturbance due asthma rescue medication use . Safety assess adverse event , lab test , urinary cortisol vital sign .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion Criteria 1 . Male Female subject 5 &lt; 12 year old . 2 . Known history moderate severe persistent reversible asthma1 ≥ 6 month prior screen visit . 3 . Demonstrated FEV1 ≥ 60 % ≤ 90 % predict normal value ( Polgar 1971 ) screen period follow appropriate withhold asthma medication ( applicable ) : No LABA use within 12 hour and/or SABA use within 6 hour PFT No use inhale ICSLABA asthma therapy within 12 hour PFT Inhaled corticosteroid allow day screen 4 . Documented reversibility ≥ 15 % FEV1 screening period 5 . Current use inhale corticosteroid asthma stable dose least 4 week prior screen visit 6 . Inadequate asthma control ICS alone dose ≤ 500 µg fluticasone equivalents/day , OR control asthma ICSLABA combination ICS dose ≤ 200 µg fluticasone equivalents/day 7 . Demonstrated satisfactory technique use pMDI spacer device 8 . Can perform spirometry adequately 9 . Willing able enter information electronic diary help parent guardian , necessary attend study visit 10 . Willing able substitute prestudy prescribe inhaled asthma medication entire duration study 11 . If female subject post menarche urine pregnancy test may undertake discretion investigator subject ' parent ( ) /legal representative . This test must negative . 12 . Written inform consent assent obtain per national law Exclusion Criteria 1 . Near fatal lifethreatening ( include intubation ) asthma within past year 2 . Hospitalisation emergency visit asthma within past 6 month 3 . History systemic ( injectable oral ) corticosteroid medication within 1 month screen visit 4 . Current prior nonresponse partial response ICSLABA combination1 5 . Evidence clinically unstable disease , determine medical history , clinical laboratory test , physical examination , Investigator 's opinion , preclude entry study . `` Clinically significant '' define disease , opinion Investigator , would put subject risk study participation , would affect outcome study 6 . In Investigator 's opinion clinically significant upper low respiratory infection within 4 week prior screen visit 7 . Significant , nonreversible active pulmonary disease ( e.g . cystic fibrosis , bronchiecstasis , tuberculosis ) 8 . Known Human Immunodeficiency Virus ( HIV ) positive status 9 . Current smoke history within 12 month prior screen visit 10 . Current evidence alcohol substance abuse within 12 month prior screen visit 11 . Subjects take β block agent , tricyclic antidepressant , monoamine oxidase inhibitor , astemizole ( Hismanal ) , quinidine type antiarrythmics , potent CYP 3A4 inhibitor ketoconazole within 1 week prior screen visit 12 . Current use medication , allow protocol , investigator 's opinion effect bronchospasm and/or pulmonary function 13 . Current evidence hypersensitivity idiosyncratic reaction test medication component 14 . Receipt Investigational medicinal product within 30 day screen visit 15 . Current participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>moderate severe persistent reversible asthma</keyword>
</DOC>